However, the FGFR1-3 inhibitor pemigatinib was recently approved for the treatment of previously treated advanced CCA with an FGFR2 fusion or other rearrangements by the FDA based on data from the FIGHT-202 trial [13]. Here, FGFR2 is linked to cholangiocarcinoma.